Search Results for "Brilinta Sales"

14:42 EST 22nd February 2017 | BioPortfolio

Matching Channels

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Sales Jobs

GE Healthcare

Ranked as the third largest medical device company in the world (based on annual sales), GE Healthcare generates $16 billion in sales each year. GEs' area of expertise is the imaging that is i...


Siemens Healthcare is the second largest medical devices company in the world (based on annual sales), with sales of $17.4 billion. Specializing in the imaging, IT, diagnostics and workflow soluti...


With annual sales reaching $15 billion in 2010, Medtronic is the 4th largest medical devices company in the world (based on annual sales). The device portfolio of Medtronic is broad; covering card...

Matching News

AstraZeneca cuts Brilinta sales hopes on artery disease failure

LONDON (Reuters) - AstraZeneca's heart drug Brilinta has failed to help patients with serious circulatory problems in their legs, prompting the company to scrap a $3.5 billion-a-year sales target for ...

BRIEF-AstraZeneca exec: $3.5 bln Brilinta sales goal no longer attainable

* Executive Ludovic Helfgott tells Reuters $3.5 billion sales goal for Brilinta no longer attainable Further company coverage: (Reporting by UK bureau)

AstraZeneca Says $3.5bn Brilinta Sales Forecast By 2023 Now Unattainable

AstraZeneca will cut its sales forecasts for Brilinta after the therapy failed to beat the older blood thinner clopidogrel in...   

AZ feels pain after heart drug fails again

AstraZeneca has admitted that its heart drug, Brilinta is unlikely meet a $3.5 billion sales target after it failed in another key trial. The large-scale EUCLID trial showed Brilinta (ticagrelor)...

AstraZeneca's Brilinta Fails Arterial Disease Drug Trial

AstraZeneca cut its sales target for prescription blood-thinning medicine Brilinta after it failed to show a benefit over standard treatment in peripheral artery disease in a large clinical trial.

AstraZeneca suffers Brilinta blow in peripheral artery disease

Anglo-Swedish pharma major AstraZeneca’s Brilinta (ticagrelor) did not demonstrate a benefit over clopidogrel…

AZ’ Brilinta disappoints in arterial disease trial

AstraZeneca's Brilinta has been hit with another setback after failing to show superiority over veteran bloodthinner clopidogrel in patients with peripheral arterial disease (PAD).

AstraZeneca's Brilinta drug fails in big arterial disease trial

LONDON (Reuters) - AstraZeneca's heart drug Brilinta has failed to help patients with serious circulatory problems in their legs, dealing a blow to a medicine that the company has tipped as a potentia...

Matching PubMed Articles

Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.

To determine the prevalence of nonprescription naloxone and sterile syringe sales, factors associated with nonprescription sales, geospatial access to nonprescription naloxone and syringe-selling phar...

Property of Fluctuations of Sales Quantities by Product Category in Convenience Stores.

The ability to ascertain the extent of product sale fluctuations for each store and locality is indispensable to inventory management. This study analyzed POS data from 158 convenience stores in Kawas...

Beverages Sales in Mexico before and after Implementation of a Sugar Sweetened Beverage Tax.

To estimate changes in sales of sugar sweetened beverages (SSB) and plain water after a 1 peso per liter excise SSB tax was implemented in Mexico in January 2014.

Iodisation of Salt in Slovenia: Increased Availability of Non-Iodised Salt in the Food Supply.

Salt iodisation is considered a key public health measure for assuring adequate iodine intake in iodine-deficient countries. In Slovenia, the iodisation of all salt was made mandatory in 1953. A consi...

Impact of CVS Pharmacy's Discontinuance of Tobacco Sales on Cigarette Purchasing (2012-2014).

To assess the impact of CVS Health's discontinuation of tobacco sales on cigarette purchasing.

Search Whole site using Google

Quick Search
Advertisement Advertisement